Orexigen (OREX) On Watch on VIVUS (VVUS) PDUFA Extension

April 9, 2012 5:47 PM EDT
Traders have their eye on Orexigen Therapeutics, Inc. (Nasdaq: OREX) after-hours Monday following news from rival VIVUS (Nasdaq: VVUS) that the FDA extended the PDUFA date for its review of the Qnexa NDA by three months, from April 17 to July 17, 2012.

Some speculators are suggesting this will assure an FDA approval of Qnexa in July.

Shares of OREX last traded at $4.09, up fractionally from th4 $4.00 close.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment